PBYI
Puma BiotechnologyBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
11
U.S. public peers
Grade Position
Above peers
vs peer average
PBYI vs peer average
70/100
PBYI vs. peer average (B vs. C)
Grade spread
A 1 · B 3 · C 1 · D 4 · F 2
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
ALLO is the first available peer comparator.
Allogene Therapeutics is another small-cap oncology biotech comp by size and financing sensitivity, but its cell-therapy pipeline and pre-commercial profile are not directly comparable to Puma's mix of marketed product revenue and pipeline optionality.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
PBYI
Puma Biotechnology
ALLO
Allogene Therapeutics
Grade
B
A
Momentum
54
96
Value
70
41
Sentiment
48
58
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs ALLO
PBYI / ALLO
Grade Position
Above peers
PBYI vs. peer average (B vs. C)
70/100
Momentum
54
ALLOValue
70
PBYISentiment
48
ALLORotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs PBYI
ALLO is the first peer returned for this comparison set.